How to access Briumvi for relapsing multiple sclerosis from Bahrain: 2026 pathway via Bahrain neurology and cross-border centres
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Bahrain runs adult neurology services through Salmaniya Medical Complex (the primary MoH tertiary hospital), King Hamad University Hospital (academic referral), Bahrain Defence Force (BDF) Hospital, Bahrain Specialist Hospital, and the American Mission Hospital network. Bahrain neurology infrastructure handles multiple sclerosis (MS) through dedicated neurology services with disease-modifying therapy (DMT) experience and cross-border referral channels to KFSHRC Riyadh and Cleveland Clinic Abu Dhabi for complex or trial-enrolment scenarios. Briumvi (ublituximab-xiiy, TG Therapeutics) was FDA-approved in December 2022 and EMA-approved in May 2023 as the third anti-CD20 biologic for relapsing MS. For a Bahrain-resident adult with confirmed relapsing-remitting MS, active secondary-progressive MS, or clinically isolated syndrome on MRI evidence, the operational question in 2026 is whether Briumvi, Ocrevus, or Kesimpta is the right fit, where the infusion is delivered, what funding pathway applies, and whether cross-border referral makes sense.
This page explains the 2026 pathway for a Bahrain-resident adult: who qualifies, where the prescribing neurologist conversation happens, how loading and maintenance infusions are coordinated locally or cross-border, what the realistic cost band looks like in BHD, what to monitor, and how the treatment plan fits into a Bahraini patient's life.
Why Briumvi, and why now
Briumvi is a glycoengineered humanised IgG1 anti-CD20 monoclonal antibody that depletes B-lymphocytes through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct B-cell apoptosis. Glycoengineering (low-fucose Fc) makes Briumvi more potent per milligram than prior anti-CD20 agents, allowing a 450 mg maintenance dose (vs Ocrevus 600 mg) and a maintenance infusion of approximately 1 hour (vs Ocrevus 3 to 4 hours). The pivotal ULTIMATE I and II trials (Steinman L et al., NEJM 2022) showed a 49 to 59 percent reduction in annualised relapse rate versus teriflunomide.
What Briumvi is, in plain language
Briumvi is an intravenous infusion administered in a hospital infusion suite. Not self-administered.
Loading: Day 1 (150 mg IV, ~4 hours total visit) and Day 15 (450 mg IV, ~3 hours total visit). Maintenance: 450 mg IV every 24 weeks (twice yearly), ~2 to 3 hours total visit.
Premedication standard: corticosteroid + antihistamine + acetaminophen.
Treatment duration is years-long. No fixed stop point.
Eligibility at a Bahrain neurology service
1. Confirmed relapsing MS by neurologist applying 2017 McDonald criteria. 2. Recent MRI brain and spine within 3 months. 3. Active disease evidence. 4. Prior DMT history typical for funding pre-authorisation. 5. Pre-treatment screening: HBV (HBsAg + anti-HBcore), JC virus serology, HIV, TB, baseline serum immunoglobulins. 6. Vaccination status review. 7. Pregnancy planning discussion.
Bahrain prescribing and supply picture
Briumvi National Health Regulatory Authority (NHRA) registration status is verified at intake. Named-patient supply via the prescribing centre's regulatory office is the parallel pathway during any registration transition. The dual NPP/domestic framing applies.
The pathway is: 1. Prescribing neurologist with MS expertise: Salmaniya Medical Complex Neurology, King Hamad University Hospital Neurology, BDF Hospital Neurology, Bahrain Specialist Hospital Neurology, American Mission Hospital Neurology, or cross-border MS centre (King Hamad University Hospital (KHUH), Salmaniya Medical Complex, Bahrain Specialist Hospital, American Mission Hospital, and Al Hilal Hospital). 2. Infusion centre logistics: Hospital infusion suite if administered locally; cross-border centre infusion suite if referred. 3. Pharmacy dispensing: Hospital pharmacy in either pathway. 4. Funding pre-authorisation: MoH funding for Bahraini nationals through the established hospital pathway. Commercial insurance for residents on case-by-case basis. Cross-border treatment funding requires separate authorisation. 5. Pre-treatment workup: HBV, JC virus, immunoglobulins, vaccinations completed before first infusion. 6. Ongoing monitoring: Neurology follow-up every 3 to 6 months. MRI annually. Quarterly IgG.
The 2026 pathway, step by step
Week 0 to 2: Documentation pack assembly. Week 2 to 6: Funding pre-authorisation review; pre-treatment screening results return. Week 6 to 8: First infusion (Day 1, 150 mg). Week 8 to 10: Second infusion (Day 15, 450 mg). Week 32: First maintenance dose. Week 56, 80, 104+: Maintenance every 24 weeks.
For cross-border pathway (King Hamad University Hospital (KHUH), Salmaniya Medical Complex, Bahrain Specialist Hospital, American Mission Hospital, and Al Hilal Hospital), add 2 to 4 weeks for cross-border referral coordination, visa logistics, and infusion-suite scheduling. The cross-border patient typically completes the pre-treatment workup in Bahrain and travels to the cross-border centre for the loading regimen, then returns for maintenance via local infusion suite or repeats cross-border travel depending on the centre relationship.
Cost expectation in BHD
US WAC ~ USD 59,000 per 450 mg infusion. MENA cash-pay band USD 45,000 to 55,000 per vial.
Year 1 total (loading + first maintenance): - USD 105,000 to 130,000 cash-pay band. - BHD 39,500 to 49,000 at 2026 indicative cross rates.
Year 2+ steady state (two infusions per year): - USD 90,000 to 110,000 cash-pay. - BHD 34,000 to 41,500 per year.
MoH-funded MS therapy for Bahraini nationals covers anti-CD20 treatment on documented eligibility. Commercial insurance for residents varies. Cross-border treatment funding has additional administrative steps.
What to monitor on Briumvi
Briumvi sits in the anti-CD20 class with Ocrevus (ocrelizumab) and Kesimpta (ofatumumab). Three safety signals stand out for an Indian patient and the treating neurology team beyond the hepatitis B screening already noted: progressive multifocal leukoencephalopathy (PML) and JC virus, persistent hypogammaglobulinaemia, and infusion reactions. Each is described below with the monitoring cadence and the prescribing-information citation.
Progressive multifocal leukoencephalopathy (PML) and JC virus. Anti-CD20 therapies including ublituximab carry a class risk for PML, a rare and serious brain infection caused by reactivation of the JC virus in immunosuppressed patients. Symptoms include progressive limb weakness, behavioural and cognitive changes, and disturbance of vision or speech. PML cases on ublituximab have been reported in the post-marketing setting (Briumvi Prescribing Information, section 5.4). Baseline JC virus antibody serology is not mandated by the FDA label before initiation, but most MS neurology programmes order it for risk stratification, particularly when sequencing onto Briumvi from natalizumab (Tysabri). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Reference: Briumvi (ublituximab-xiiy) Prescribing Information, TG Therapeutics, section 5.4, US FDA approval December 2022.
Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Briumvi label requires baseline measurement of serum IgG, IgA, and IgM before treatment initiation, with monitoring during treatment and after discontinuation until B-cell repletion (Briumvi Prescribing Information, section 5.5). Indian MS-experienced centres typically check quantitative immunoglobulins at baseline and every six months at the maintenance-infusion visit. Persistent hypogammaglobulinaemia, in particular IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Briumvi Prescribing Information, section 5.5; Steinman L et al., Ublituximab versus teriflunomide in relapsing multiple sclerosis (ULTIMATE I and II), N Engl J Med 2022;387(8):704-714.
Infusion reactions and premedication. Infusion reactions are the most frequent adverse event in the ULTIMATE I and II trials, occurring in approximately 48 percent of Briumvi-treated patients and most often with the first (Day 1, 150 mg) infusion. Premedication is mandatory before each infusion: methylprednisolone 100 mg IV (or equivalent corticosteroid) approximately 30 minutes pre-infusion, plus an oral or IV antihistamine such as diphenhydramine 25 to 50 mg, plus an antipyretic such as paracetamol 650 mg orally (Briumvi Prescribing Information, section 5.1, dosing and administration). The first 150 mg infusion is delivered over approximately 4 hours with continuous observation; the 450 mg doses run over approximately 1 hour if the Day 1 infusion was tolerated. Reactions may present as throat tightness, flushing, headache, fever, urticaria, bronchospasm, or hypotension and are managed by slowing or temporarily stopping the infusion, optimising premedication, and observing recovery before resuming. Severe reactions, including anaphylaxis, require permanent discontinuation. References: Briumvi Prescribing Information, section 5.1 and dosing schedule; TG Therapeutics infusion administration guide.
Religious, ethical, and family-logistics framing
Briumvi is a recombinant humanised IgG1 antibody. No donor element, no human tissue source. The classical analogy to vaccines and biologics holds in MENA Islamic medical ethics.
Twice-yearly infusion cadence: two clinic days per year. No daily pill, no weekly injection.
For cross-border pathway, family-logistics planning includes visa, accommodation, and a companion-traveller arrangement for the loading regimen visits.
Pregnancy planning: contraception during treatment and for 6 months after last infusion.
When Briumvi is not the right call
For Bahrain patients with well-controlled MS on moderate-efficacy oral DMT, primary-progressive MS (Briumvi not indicated), low baseline immunoglobulins, untreated chronic HBV, or imminent pregnancy plans:
- Ocrevus: IV anti-CD20, similar efficacy, longer infusion, PPMS approved. - Kesimpta: SC monthly home-administered anti-CD20. - Off-label rituximab: off-label in MS, used in some MENA centres. - Natalizumab (Tysabri): non-anti-CD20 high efficacy. - High-efficacy oral agents: cladribine, siponimod, ozanimod. - Moderate-efficacy oral agents: teriflunomide, dimethyl fumarate, fingolimod.
Reserve Meds does not promote one anti-CD20 MS therapy over another.
What Reserve Meds does on this case
We are a US-based concierge coordinator. Not the prescriber, not the dispensing pharmacy. On a Bahrain Briumvi case we build the documentation pack with the treating neurologist's office, run the funding pre-authorisation conversation (including cross-border funding if applicable), coordinate the pre-treatment workup with the prescribing centre's laboratory, organise the infusion-suite scheduling (locally or cross-border), and stay with the case through the first 18 months. Clinical decisions remain with your treating neurologist.
Frequently asked patient questions
How is Briumvi different from Ocrevus? Shorter maintenance infusion (~1 hour vs 3 to 4 hours).
Will I need to stop my current MS medication? Most prior DMTs require washout.
How long do I take Briumvi for? For as long as it controls your MS.
Can I get pregnant on Briumvi? Contraception during treatment and for 6 months after last infusion.
Can I have my Briumvi infusions in Bahrain or do I need to travel? Bahrain MS centres handle anti-CD20 infusions. Cross-border referral to KFSHRC Riyadh or Cleveland Clinic Abu Dhabi is an option for complex cases, trial enrolment, or where Briumvi supply is not locally available at the time of initiation.
What does the infusion day look like? Day 1: ~4 hours. Day 15: ~3 hours. Maintenance: ~2 to 3 hours.
Next steps
If you are a Bahrain-resident adult with relapsing MS considering Briumvi, the next step is the conversation with your treating neurologist. Reserve Meds coordinates the documentation pack, funding pre-authorisation, and infusion-suite scheduling once the prescribing decision is in place.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.